Evaluation of Technological Innovation in Radiotherapy (PERA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03378856|
Recruitment Status : Recruiting
First Posted : December 20, 2017
Last Update Posted : August 9, 2022
Prospective cohort study of patients receiving standard-care radiotherapy is paramount to a better understanding of radiation effects and longterm outcomes.
The primary objective is to determine the feasibility of establishing infrastructure to systematically collect clinical data, patient-reported outcomes, and imaging data from daily radiotherapy practice.
Secondary objectives are to provide a control cohort for comparative effectiveness research of investigational interventions through a cmRCT design; compare imaging features with clinical outcomes; understand dose-effect relationships; quantify imaging quality metrics.
|Condition or disease|
|Cancer Radiotherapy Side Effect|
The study consists of an effort to develop infrastructure that will support systematic collection of data from daily radiotherapy practice. At the core, PERA is a large observational cohort study, serving as a multiple cohort randomized trial and image banking facility. It includes consent for the collection of imaging data, patient-reported outcomes, and broad randomization for studies according to the innovative cohort multiple randomized controlled trial design (cmRCT).
The basis of this design is a prospective cohort of participants receiving care as usual, who give informed consent for cohort participation.
Participants can furthermore be asked for informed consent to be randomized in future RCTs conducted within the cohort. Participants are informed that they will be offered an experimental intervention if they are randomly selected. They are also informed that they otherwise might serve as controls without being notified and that their data can be used in a trial context. For each participant in the cohort, PROs are captured at baseline and at regular intervals during follow-up. Within this cohort, multiple RCTs can be conducted. The design is especially attractive for clinical research areas with rapid evolution of technology, and for highly desired or expensive interventions.
In the first stage, at entry into the cohort, all potential participants are asked for their informed consent to participate in a cohort study and broad consent to be either randomly selected to be approached for experimental interventions or to serve as control without further notice during participation in the cohort. In a second stage, at the initiation of an RCT within the cohort, informed consent to receive the intervention is then only sought in those randomly selected for the intervention arm. At the third stage, after completion of each RCT, all cohort participants receive aggregate disclosure of trial results.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||1200 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Partnership Initiative for the Evaluation of Technological Innovation in Radiotherapy|
|Actual Study Start Date :||November 1, 2017|
|Estimated Primary Completion Date :||October 2025|
|Estimated Study Completion Date :||October 2025|
- Accrual rates [ Time Frame: 2 years ]Determine feasibility of achieving high accural rates (greater than 80%) with this approach.
- Number of cmRCT trials activated [ Time Frame: 2 years ]Measure if success would be the activation of 2 or more trials in the time frame.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03378856
|Contact: Cynthia Ménard, MD, M.Sc||514-890-8254||Cynthia.Menard@umontreal.ca|
|London Health Regional Cancer Centre||Not yet recruiting|
|London, Ontario, Canada|
|Contact: Karen Eddy firstname.lastname@example.org|
|Princess Margaret Cancer Centre||Not yet recruiting|
|Toronto, Ontario, Canada|
|Contact: Philip Wong email@example.com|
|Centre de santé et de services sociaux de Laval||Recruiting|
|Laval, Quebec, Canada|
|Contact: Marie-Andrée Fortin, MD|
|Centre Hospitalier de l'Université de Montréal||Recruiting|
|Montréal, Quebec, Canada|
|Contact: Diane Trudel 514-890-8000 ext 26906 firstname.lastname@example.org|
|CHUQ||Not yet recruiting|
|Québec, Quebec, Canada|
|Contact: Sophie Pouliot 4185254444 ext 67307 email@example.com|